Sangamo Therapeutics, Inc. SGMO Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sangamo Therapeutics, Inc. SGMO

SGMO 0.532

+7.9%

3:45 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scott_jiminez who wrote (63)	1/17/2001 10:38:24 AM
From: donald sew	Read Replies (1) of 368

Scott, >>>> In vivo and de novo VEGF regulation could be huge if SGMO can construct ZPF(s) to block tumor-associated vascularization. <<<< I too feel that the potential for SGMO is huge, but could still be years before the actual products are in place. As it was explained to me in layman terms, SGMO has the technology, which they bought from JOHNs HOPKINs, to attached enzymes(organic or artificial) to specific locations on the DNA DOUBLE HELIX. Once attached the enzymes then acts like a scissors and cuts the double helix at that specific location. Amazing technology. I also understand that other independent labs are now using their technology in other areas of research. Believe one in UTAH and another somewhere in EUROPE. Again, but to assume that a product is forthcoming soon may be premature, nevertheless the potential could be huge.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next